Generic Name and Formulations:
Chloroprocaine HCl 10mg/mL, 20mg/mL; soln for inj; contains methylparaben.
Fresenius Kabi USA
Indications for NESACAINE:
Production of local anesthesia by infiltration and peripheral nerve block.
Epidural anesthesia: administer test dose first; monitor for CNS or cardiovascular toxicity. See literature for dosing based on procedure. Individualize. Max single recommended dose: 11mg/kg, not to exceed max total dose of 800mg. Debilitated, elderly, acutely ill (cardiac and/or liver disease): reduce dose.
<3yrs: see literature. Individualize based on age and weight. ≥3yrs: max 11mg/kg.
Not for subarachnoid administration. Lumbar and caudal epidural anesthesia: caution with existing neurological disease, spinal deformities, septicemia, severe hypertension. To be administered under the supervision of experienced clinicians. Have intubation, artificial respiration, oxygen therapy and reversal agents available. Hypotension. Heart block. Monitor cardiovascular and respiratory vital signs. Hepatic impairment. Retrobulbar block. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Concomitant sulfonamides: not recommended.
CNS effects (eg, excitation, depression, restlessness, anxiety, dizziness, tremors), cardiovascular effects (eg, myocardium depression, decreased cardiac output, heart block, hypotension, bradycardia, ventricular arrhythmias, cardiac arrest), allergic-type reactions, neurologic effects (eg, spinal block, urinary retention, paresthesia, weakness, headache, paralysis of lower extremities).
Nesacaine: Multi-dose vial (30mL)—1; Nesacaine-MPF: Single-dose vial (20mL)—1
Clinical Pain Advisor Articles
- Opioid Use Disorders: Advances in Pharmacotherapy Provide Long-term Results
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- FDA Taps Social Media to Identify and Assess Emerging Drug Abuse Threats
- Buffered Lidocaine May Be Superior to Nonbuffered Lidocaine for Inferior Alveolar Nerve Block
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Marijuana's Uncertain Status: Closing the Gap Between State and Federal Policies